Etiopathogenesis of basedow’s disease: Trends and current aspects;Äthiopathogenese des morbus basedow: Trends und aktuelles

NuklearMedizin

Volumn 54, Issue 5, 2015, Pages 204-210

  Leporati, P ^a   Groppelli, G ^a   Zerbini, F ^a   Rotondi, M ^a   Chiovato, L ^a  

^a UNIVERSITY OF PAVIA   (Italy)

Author keywords

Autoimmunity; Basedow; Chemokines; Graves; Thyroid

Indexed keywords

CD16 ANTIGEN; CD40 ANTIGEN; CHEMOKINE RECEPTOR CXCR3; CXCL9 CHEMOKINE; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; GAMMA INTERFERON; GAMMA INTERFERON INDUCIBLE PROTEIN 10; INTERLEUKIN 2 RECEPTOR ALPHA; NON RECEPTOR PROTEIN TYROSINE PHOSPHATASE 22; TOLL LIKE RECEPTOR; TRANSCRIPTION FACTOR FOXP3; CHEMOKINE;

ANTIGEN PRESENTATION; ARTICLE; CELL DIFFERENTIATION; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC PREDISPOSITION; GENETIC SUSCEPTIBILITY; GENETIC TRANSCRIPTION; GENETIC VARIABILITY; GRAVES DISEASE; HUMAN; IMMUNE RESPONSE; MAJOR HISTOCOMPATIBILITY COMPLEX; MICROCHIMERISM; REGULATORY T LYMPHOCYTE; SINGLE NUCLEOTIDE POLYMORPHISM; BIOLOGICAL MODEL; GENETICS; IMMUNOLOGY; THYROID GLAND;

CHEMOKINES; GENETIC PREDISPOSITION TO DISEASE; GRAVES DISEASE; HUMANS; MODELS, GENETIC; MODELS, IMMUNOLOGICAL; THYROID GLAND;

EID: 84948947187     PISSN: 00295566     EISSN: None     Source Type: Journal    
DOI: 10.3413/Nukmed-0739-15-04     Document Type: Article

References (48)

1. Antonelli A, Fallahi P, Rotondi M et al. Increase of interferon-gamma inducible alpha chemokine CXCL10 serum levels in patients with active Graves’ disease, and modulation by methimazole therapy and thyroidectomy. Br J Surg 2006; 93: 1226–1231.
2. Antonelli A, Rotondi M, Fallahi P et al. Increase of interferon-gamma-inducible CXC chemokine CXCL10 serum levels in patients with active Graves’ disease, and modulation by methimazole therapy. Clin Endocrinol (Oxf) 2006; 64: 189–195.
3. Armitage RJ, Macduff BM, Spriggs MK et al. Human B cell proliferation and Ig secretion induced by recombinant CD40 ligand are modulated by soluble cytokines. J Immunol 1993; 150: 3671–3680.
4. Ban Y, Davies TF, Greenberg DA et al. Arginine at position 74 of the HLA-DRb1 chain is associated with Graves’ disease. Genes Immun 2004; 5: 203–208.
5. Bartalena L, Fatourechi V. Extrathyroidal manifestations of Graves’ disease: a 2014 update. J Endocrinol Invest 2014; 37: 691–700.
6. Bartalena L, Macchia PE, Marcocci C et al. Effects of treatment modalities for Graves’ hyperthyroidism on Graves’ orbitopathy: a 2015 Italian Society of Endocrinology Consensus Statement. J Endocrinol Invest 2015; 38: 481–487.
7. Bernecker C, Halim F, Lenz L et al. microRNA expressions in CD4+ and CD8+ T-cell subsets in autoimmune thyroid diseases. Exp Clin Endocrinol Diabetes 2014; 122: 107–112.
8. Bottazzo GF, Pujol-Borrell R, Hanafusa T et al. Role of aberrant HLA-DR expression and antigen presentation in induction of endocrine autoimmunity. Lancet 1983; 2: 1115–1118.
9. Brix TH, Hansen PS, Kyvik KO et al. Aggregation of thyroid autoantibodies in twins from oppositesex pairs suggests that microchimerism may play a role in the early stages of thyroid autoimmunity. J Clin Endocrinol Metab 2009; 94: 4439–4443.
10. Brix TH, Kyvik KO, Christensen K et al. Evidence for a major role of heredity in Graves’ disease: a population-based study of two Danish twin cohorts. J Clin Endocrinol Metab 2001; 86: 930–934.
11. Chailurkit LO, Aekplakorn W, Ongphiphadhanakul B. The relationship between circulating estradiol and thyroid autoimmunity in males. Eur J Endocrinol 2013; 170: 63–67.
12. Chen W, Lin H, Wang M. Immune intervention effects on the induction of experimental autoimmune thyroiditis. J Huazhong Univ Sci Technol Med Sci 2002; 22: 343–345.
13. Chu X, Pan CM, Zhao SX et al. A genome-wide association study identifies two new risk loci for Graves’ disease. Nat Genet 2011; 43: 897–901.
14. Cloutier JF, Veillette A. Cooperative inhibition of T-cell antigen receptor signaling by a complex between a kinase and a phosphatase. J Exp Med 1999; 189: 111–121.
15. Colobran R, Armengol Mdel P, Faner R et al. Association of an SNP with intrathymic transcription of TSHR and Graves’ disease: a role for defective thymic tolerance. Hum Mol Genet 2011; 20: 3415–3423.
16. Corona G, Biagini C, Rotondi M et al. Correlation between, clinical, biochemical, color doppler ultrasound thyroid parameters, and CXCL-10 in autoimmune thyroid diseases. Endocr J 2008; 55: 345–350.
17. Costagliola S, Many MC, Denef JF et al. Genetic immunization of outbred mice with thyrotropin receptor cDNA provides a model of Graves’ disease. J Clin Invest 2000; 105: 803–811.
18. Davies TF. Infection and autoimmune thyroid disease. J Clin Endocrinol Metab 2008; 93: 674–676.
19. Davies TF. Really significant genes for autoimmune thyroid disease do not exist--so how can we predict disease? Thyroid 2007; 17: 1027–1029.
20. De Groot L, Abalovich M, Alexander EK et al. Management of thyroid dysfunction during pregnancy and postpartum: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2012; 97: 2543–2565.
21. Duntas LH. A tribute to Carl Adolph von Basedow: to commemorate 150 years since his death. Hormones (Athens) 2004; 3: 208–209.
22. Duntas LH. Selenium and the thyroid: a close-knit association. J Clin Endocrinol Metab 2010; 95: 5180–5188.
23. Inukai Y, Momobayashi A, Sugawara N et al. Changes in expression of T-helper (Th) 1- and Th2-associated chemokine receptors on peripheral blood lymphocytes and plasma concentrations of their ligands, interferon-inducible protein-10 and thymus and activation-regulated chemokine, after antithyroid drug administration in hyperthyroid patients with Graves’ disease. Eur J Endocrinol 2007; 156: 623–630.
24. Kaithamana S, Fan J, Osuga Y et al. Induction of experimental autoimmune Graves’ disease in BALB/c mice. J Immunol 1999; 163: 5157–5164.
25. Laurberg P, Cerqueira C, Ovesen L et al. Iodine intake as a determinant of thyroid disorders in populations. Best Pract Res Clin Endocrinol Metab 2010; 24: 13–27.
26. Marcocci C, Bartalena L. Role of oxidative stress and selenium in Graves’ hyperthyroidism and orbitopathy. J Endocrinol Invest 2013; 36: 15–20.
27. Marinò M, Latrofa F, Menconi F et al. An update on the medical treatment of Graves’ hyperthyroidism. J Endocrinol Invest 2014; 37: 1041–1048.
28. Marinò M, Latrofa F, Menconi F et al. Role of genetic and non-genetic factors in the etiology of Graves’ disease. J Endocrinol Invest 2015; 38: 283–294.
29. McLachlan SM, Nagayama Y, Rapoport B. Insight into Graves’ hyperthyroidism from animal models. Endocr Rev 2005; 26: 800–832.
30. McLachlan SM, Rapoport B. Breaking tolerance to thyroid antigens: changing concepts in thyroid autoimmunity. Endocr Rev 2014; 35: 59–105.
31. Nagayama Y, Kita-Furuyama M, Ando T et al. A novel murine model of Graves’ hyperthyroidism with intramuscular injection of adenovirus expressing the thyrotropin receptor. J Immunol 2002; 168: 2789–2794.
32. Paunkovic N, Paunkovic J, Pavlovic O et al. The significant increase in incidence of Graves’ disease in eastern Serbia during the civil war in the former Yugoslavia (1992 to 1995). Thyroid 1998; 8: 37–41.
33. Piantanida E, Tanda ML, Lai A et al. Prevalence and natural history of Graves’ orbitopathy in the XXI century. J Endocrinol Invest 2013; 36: 444–449.
34. Purves HD, Adams DD. Thyroid-stimulating hormone. Br Med Bull 1960; 16: 128–132.
35. Romagnani P, Rotondi M, Lazzeri E et al. Expression of IP-10/CXCL10 and MIG/CXCL9 in the thyroid and increased levels of IP-10/CXCL10 in the serum of patients with recent-onset Graves’ disease. Am J Pathol 2002; 161: 195–206.
36. Rotondi M, Chiovato L. The chemokine system as a therapeutic target in autoimmune thyroid diseases: A focus on the interferon-γ inducible chemokines and their receptors. Curr Pharm Des 2011; 17: 3202–3216.
37. Rotondi M, Chiovato L. Vitamin D deficiency in patients with Graves’ disease: probably something more than a casual association. Endocrine 2013; 43: 3–5.
38. Rotondi M, Cappelli C, Pirali B et al. The effect of pregnancy on subsequent relapse from Graves’ disease after a successful course of antithyroid drug therapy. J Clin Endocrinol Metab 2008; 93: 3985–3988.
39. Rotondi M, Chiovato L, Romagnani S et al. Role of chemokines in endocrine autoimmune diseases. Endocr Rev 2007; 28: 492–520.
40. Rotondi M, Pirali B, Lodigiani S et al. The post partum period and the onset of Graves’ disease: an overestimated risk factor. Eur J Endocrinol 2008; 159: 161–165.
41. Shimojo N, Kohno Y, Yamaguchi K-I et al. Induction of Graves-like disease in mice by immunization with fibroblasts transfected with the thyrotropin repector and a class II molecule. Proc Natl Acad Sci USA 1996; 93: 11074–11079.
42. Simmonds MJ, Kavvoura FK, Brand OJ et al. Skewed X chromosome inactivation and female preponderance in autoimmune thyroid disease: an association study and meta-analysis. J Clin Endocrinol Metab 2014; 99: E127–E131.
43. Teft WA, Kirchhof MG, Madrenas J. A molecular perspective of CTLA-4 function. Annu Rev Immunol 2006; 24: 65–97.
44. Teng X, Shan Z, Teng W et al. Experimental study on the effects of chronic iodine excess on thyroid function, structure, and autoimmunity in autoimmune-prone NOD.H-2h4 mice. ClinExp Med 2009; 9: 51–59.
45. Tomer Y. Genetic susceptibility to autoimmune thyroid disease: past, present, and future. Thyroid 2010; 20: 715–725.
46. Weetman AP. Immune reconstitution syndrome and the thyroid. Best Practice and Research in Clinical Endocrinology and Metabolism 2009; 23: 693–702.
47. Wiersinga WM. Smoking and thyroid. Clin Endocrinol 2013; 79: 145–151.
48. Yin X, Sachidanandam R, Morshed S et al. mRNASeq reveals novel molecular mechanisms and a robust fingerprint in Graves’ disease. J Clin Endocrinol Metab 2014; 99: E2076–2083